Rallybio (RLYB) announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia. The company’s decision to discontinue RLYB212 development was based on pharmacokinetic data from the Phase 2 clinical trial demonstrating the inability of the RLYB212 dose regimen to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy. Rallybio remains focused on advancing RLYB116, a once-weekly low volume C5 inhibitor for the treatment of complement-driven diseases, as well as its emerging preclinical programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
- Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
- Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
- Rallybio Corporation Reports 2024 Financial Results and Progress
- Promising Developments and Financial Stability Support Buy Rating for Rallybio
- Rallybio reports Q4 EPS (25c), consensus (30c)